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, and has subsequently spread through hospitals worldwide. 1 The acquisition of antimicrobial resistance provides a selective advantage in the nosocomial environment, and has complicated treatment regimens significantly. Today, MRSA is a major cause of morbidity and mortality in hospitals and the community. [2] [3] [4] [5] [6] [7] Circulating MRSA clones vary between hospital and community settings. A small number of MRSA clones have dominated globally in hospital settings, and progressive waves of different clones have occurred over time. 8, 9 Currently, sequence type (ST) 22 (EMRSA-15) has been growing in importance in the UK, Europe, South-East Asia (i.e. Singapore) and Australia, and is replacing other MRSA clones (ST36 or EMRSA-16 in the UK, ST239 in Singapore and Australia). [10] [11] [12] [13] This study was performed to determine the relative prevalence of the healthcare-associated MRSA (HA-MRSA) clones ST22 and ST239 in a tertiary referral centre and affiliated hospitals in Melbourne, Australia. Clinical features were compared and differences were identified between these two clones to further our epidemiological understanding of why ST22 is increasingly prevalent. Table A , online supplementary material). MRSA isolates resistant to at least three non-beta-lactam antibiotics in different antibiotic classes were defined as multi-resistant MRSA (lincosamides and macrolides were considered a single antibiotic class); all other isolates were non-multi-resistant MRSA. 14 Isolates were typed using a multi-locus sequence typing (MLST)-based high-resolution melting scheme that provides inferred MLST clonal complexes (CC), as described previously. 15 Isolates typed as CC22 and CC239 have previously been determined to represent ST22 and ST239 accurately in this context. 15 It was confirmed that the antibiograms of those typed as CC22 or CC239 were consistent with the typical antibiograms of known ST22 and ST239. 13 
<B>Clinical details and definitions
Demographic and clinical data were collected on all patients by chart review. For the purposes of this study, patients occupying LTCF beds at Alfred Health were considered as community LTCF
residents rather than Alfred Health inpatients. MRSA infections were defined as healthcareassociated if any of the following criteria were met: 16 (a) discharge from a healthcare facility within the previous 30 days; (b) resident of a LTCF; (c) current haemodialysis, day oncology, home nursing or hospital in the home patient; or (d) if MRSA was isolated from a specimen collected >48 h after hospital admission. All other infections were considered to be community-associated.
Healthcare-associated infections were further divided into nosocomial and non-nosocomial.
Nosocomial healthcare-associated infections represented MRSA acquired in the hospital setting (i.e.
history of acute hospital admission within the last 30 days, or MRSA isolation >48 h after current hospital admission) and non-nosocomial healthcare-associated infections represented all other healthcare-associated infections. An implant-related infection was assumed if the isolate was recovered from a site directly involving a foreign body (e.g. intravascular catheter, indwelling urethral catheter, orthopaedic fixation device). For the purposes of this study, isolates for which a clinical syndrome was documented and specific treatment was provided were deemed to be clinically significant. Isolates that were not treated were deemed to be clinically non-significant. aureus/MRSA epidemiology.
<B>Ethics and statistics
Ethical approval for this study was granted by the Alfred Health Ethics Committee (Project No.:
25/13). Figure 1 ).
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<insert Figure 1 near here>
The antibiogram for the 78 CC22 isolates was typical for ST22 EMRSA-15, with all isolates resistant to ciprofloxacin and 71% of isolates resistant to erythromycin. Almost all CC239 isolates were multi-resistant (139/142, 98%), typically to tetracycline, erythromycin, co-trimoxazole, gentamicin and ciprofloxacin (see Table B , online supplementary material).
Although the proportion of sterile site S. aureus isolates that were MRSA decreased from 26% to 19% between 2010 and 2014, this did not reach statistical significance (P=0.3).
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Complete clinical data were available for 208 of 220 (95%) patients with CC22 or CC239 MRSA.
In 126 of these patients, the isolate was considered to be a clinically significant pathogen. The clinical syndromes associated most commonly with CC22 or CC239 were skin and soft tissue infections (SSTIs; 74/126, 59%), respiratory tract infections including pneumonia (26/126, 21%), osteo-articular infections (17/126, 13%) and urinary tract infections (5/126, 4%). Seventy-one of the 220 (32%) CC22/CC239 patients had blood cultures performed, and six of these patients were CC22/CC239 blood culture positive.
The key differences between patients from whom CC22 or CC239 MRSA were isolated are presented in Table I . For the subgroup of inpatients, multi-variate logistic regression showed that, in comparison with CC239, CC22 was associated with older patients [adjusted odds ratio (aOR) 1.04
for each year increase, 95% confidence interval (CI) 1.02-1.07] and resident in LTCFs (aOR 5.5, 95% CI 2.0-14.5). When outpatients were included in the model, CC22 was also independently associated with patients from subacute hospitals relative to CC239 (aOR 2.7, 95% CI 1.2-5.8).
<insert Table I near here>
<B>CC22 and CC239 have different epidemiological niches
Both CC22 and CC239 were predominantly healthcare associated (Table I) ; however, the nature of the healthcare association differed for each strain. The healthcare association of CC22 was more likely to be LTCF residence compared with CC239 (42% vs 6%, P<0.0001).
CC239 was the major nosocomial MRSA, representing 58% of all nosocomial isolates, although this proportion varied between inpatient units (Table II) In contrast, CC22 was commonly recovered from patients presenting from LTCFs, and accounted for 38% of MRSA from LTCFs compared with 11% for CC239. Additionally, CC22
represented 47% of MRSA isolates recovered from patients admitted under general medicine, which typically cares for older patients, commonly from LTCFs, with multiple comorbidities.
<B>Rise of CC22 and fall of CC239 from 2003 to 2011
To determine if epidemiological shifts seen over time at Alfred Health reflected broader changes in Australia, the proportions of MRSA due to CC22 and CC239 were compared at hospital (Alfred clinical epidemiology of CC22 with other clones. 10, 13, [21] [22] [23] This study identified significant risk factors for CC22 relative to CC239, including older age, LTCF residence and admission to a subacute healthcare facility. In contrast, CC239 is primarily a nosocomial pathogen, with acquisition and transmission occurring within the acute care hospital system. These findings provide a key insight into the reasons for the growing prominence of CC22 MRSA, particularly in the context of an ageing demographic and expanding LTCF resident population. In Australia, the proportion of those aged >65 years has increased from 13% to 15% over the past 10 years. 24 In Europe and Australia, there has been a gradual decline in the proportion of MRSA among all S. aureus isolates. 12,25 These trends likely reflect the impact of a number of initiatives (e.g.
antimicrobial stewardship, handwashing, patient isolation) rather than any single intervention. The limited local data for invasive infection isolates demonstrate a similar trend, with a reduction in the proportion of S. aureus being MRSA from 26% to 19% over a five-year period (not statistically significant). Clearly, ongoing surveillance of MRSA rates and circulating MRSA clones is important to monitor the dynamic epidemiology of MRSA, and identify the key drivers behind MRSA reservoirs and spread.
In this study, many of the CC22 MRSA patients admitted to the general medicine units at Alfred Health and the subacute hospitals were from LTCFs. As the median time for recovery of CC22 MRSA was only one day after admission, it appears that many elderly LTCF patients harbour CC22 MRSA prior to hospital admission, and LTCFs have become CC22 MRSA reservoirs. This is M A N U S C R I P T
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11 consistent with the UK, where CC22 has been reported to be the predominant MRSA clone in LTCF residents, and circulating hospital MRSA clones often reflect those in neighbouring LTCFs. 26, 27 The epidemiology of CC239 MRSA stands in stark contrast. Patients with CC239 MRSA were younger and the median time for recovery of CC239 was nine days after admission. However, established infection control strategies directed at MRSA are difficult to implement in LTCFs. 26 Notably, screening for MRSA colonization is not routine in Australian LTCFs, nor is screening of patients admitted from LTCFs to the hospitals in this study.
The burden of CC22 MRSA is large and represents a potential target for infection control strategies. While inferences on the direction of spread of CC22 MRSA between LTCFs and hospital cannot be made definitively on the basis of this study, a group of patients that may be acting as a reservoir for CC22 MRSA was identified. This group is therefore appropriate for interventions targeted at reducing the CC22 MRSA burden. However, the optimal strategy for screening, intervening and reducing the MRSA burden remains controversial ('search and destroy' approach, M A N U S C R I P T
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'bundles of care', decolonization, barrier precautions, terminal cleaning and hand hygiene have all been employed with varying success), particularly in LTCFs. [30] [31] [32] [33] [34] Interestingly, CC239 was frequently isolated from patients with CF. Alfred Health is a specialist treatment and referral centre for CF and lung transplant patients. MRSA infection has been linked independently to poorer outcomes in patients with CF, but determination of MRSA strain types and dynamics in adult patients with CF has been limited. [35] [36] [37] Available data show a predominance of healthcare MRSA strains, as seen in this study, with minimal temporal strain variation in individuals. In lung transplant recipients, MRSA also leads to increased morbidity, and healthcare-associated MRSA strain types similar to those described in this study predominate. 38, 39 Whether or not these CC239 are clonal and represent patient-to-patient transmission in the CF and lung transplant patient population warrants further investigation with higher resolution typing methods.
Although this study concentrated on a single healthcare system in Melbourne, the patterns of change in MRSA clones at the Alfred Hospital reflect those seen elsewhere in Australia. Similarly, there are parallels in the replacement of other MRSA clones by CC22 MRSA elsewhere in the world. 10, 11 Furthermore, the diversity of services offered by the three hospitals studied provides a useful counterpoint to elucidate differences in the populations affected by CC22 compared with CC239. This study's a-priori definition of clinically significant infections, that included information on whether or not antibiotics were prescribed, may have underestimated the number of clinically significant infections, as a minority of patients may have been deemed unsuitable for treatment and therefore the infection was not treated. In contrast, given that antibiotic over-prescribing is well recognized and that a large number of isolates were from non-sterile sites, the surrogate of antibiotic prescription may have actually overestimated true infections. Although the typing method used in this study provides a rapid and cost-effective means of assigning isolates to the CC level, this study would have been able to draw stronger inferences regarding transmission and hospital acquisition if higher resolution typing, such as whole genome sequencing, had been performed.
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<A>Conclusions
Healthcare MRSA strains CC22 and CC239 accounted for the majority of MRSA morbidity, but each clone has a particular epidemiological niche. CC22 is common in the elderly and LTCF residents, and was typically introduced into the hospital system by these patient groups. CC239
MRSA transmission was predominantly nosocomial and was identified as a major MRSA strain in
ICUs and respiratory and vascular surgery units. These findings suggest that targeted interventions effective at reducing transmission for one clone are unlikely to be as effective for the other clone.
As CC22 gains in prominence, infection control strategies involving LTCFs and their residents will become increasingly important to achieve continued reductions in rates of MRSA infections. Data expressed as N (% or row) unless otherwise specified.
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P-values refer to comparison of respective proportions of CC22 and CC239 by Fisher's exact test. 
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